Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Open Access
- 28 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 85 (5), 831-842
- https://doi.org/10.1007/s00280-020-04054-8
Abstract
Purpose The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics (PK) and drug–drug interaction (DDI) for pola. Methods Six or eight cycles of pola 1.0–1.8 mg/kg were administered intravenously every 3 weeks (q3w) with R/G-CHP. Exposures of pola [including antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE] and R/G-CHP were assessed by non-compartmental analysis and/or descriptive statistics with cross-cycle comparisons to cycle 1 and/or after multiple cycles. Pola was evaluated as a potential victim and perpetrator of a PK drug–drug interaction with R/G-CHP. Population PK (popPK) analysis assessed the impact of prior treatment status (naïve vs. relapsed/refractory) on pola PK. Results Pola PK was similar between treatment arms and independent of line of therapy. Pola PK was dose proportional from 1.0 to 1.8 mg/kg with R/G-CHP. Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively. acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week). Unconjugated MMAE exhibited formation rate-limited kinetics. Exposures of pola with R/G-CHP were similar to those in the absence of CHP; exposures of R/G-CHP in the presence of pola were comparable to those in the absence of pola. Conclusions Pola PK was well characterized with no clinically meaningful DDIs with R/G-CHP. Findings are consistent with previous studies of pola + R/G, and support pola + R/G-CHP use in previously untreated diffuse large B-cell lymphoma.Keywords
Funding Information
- F. Hoffmann-La Roche Ltd
This publication has 44 references indexed in Scilit:
- Antibody–drug conjugates: current status and future directionsDrug Discovery Today, 2013
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Management and Research, 2013
- Therapeutic Protein Drug–Drug Interactions: Navigating the Knowledge Gaps–Highlights from the 2012 AAPS NBC Roundtable and IQ Consortium/FDA WorkshopThe AAPS Journal, 2013
- Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paperBioanalysis, 2013
- Drug–Drug Interaction Studies: Regulatory Guidance and An Industry PerspectiveThe AAPS Journal, 2013
- Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeuticsBioanalysis, 2013
- Therapeutic potential of an anti-CD79b antibody–drug conjugate, anti–CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphomaBlood, 2009
- Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphomaExpert Opinion on Pharmacotherapy, 2009
- Drug Interaction Studies of Therapeutic Proteins or Monoclonal AntibodiesThe Journal of Clinical Pharmacology, 2007
- Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphomaBlood, 2007